Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
E-pub ahead of print

Outcome of healing after dental implant placement in patients with cancer on high-dose antiresorptive medications: a prospective feasibility study

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Complications related to bone augmentation procedures of localized defects in the alveolar ridge. A retrospective clinical study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Ten-year retrospective study of head and neck carcinoma in situ: incidence, treatment, and clinical outcome

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Implant treatment after traumatic tooth loss: A systematic review

    Research output: Contribution to journalReviewResearchpeer-review

  2. Bone Regeneration in Membrane-Protected Defects

    Research output: Chapter in Book/Report/Conference proceedingBook chapterResearch

  3. Soft tissue management at implants: Summary and consensus statements of group 2. The 6th EAO Consensus Conference 2021

    Research output: Contribution to journalReviewResearchpeer-review

  4. Fully versus conventionally guided implant placement by dental students: A randomized controlled trial

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

PURPOSE: Implant placement in patients with cancer receiving high-dose antiresorptive medication (HDAR) is considered contraindicated. This prospective, feasibility study tested the hypothesis that dental implants can be placed in such patients by applying a staged implant placement protocol with submerged healing.

METHODS: Three groups of patients on HDAR were included as follows: group 1: patients who underwent tooth extraction, without the development of medication-related osteonecrosis of the jaws (MRONJ); group 2: patients with surgically treated MRONJ who had demonstrated clinical healing for at least 3 months; group 3: patients with established MRONJ who was planned for surgical resection and simultaneous implant placement.

RESULTS: A total of 49 implants were placed in 27 patients (group 1: 12, group 2: 7 and group 3: 8). HDAR included bisphosphonates and denosumab. The mean HDAR time was 25 months (SD: ± 18.4, range 3-68 months). An abutment operation was performed 4 months following the implant placement (SD: ± 1.9, range 3-14 months). All patients healed uneventfully.

CONCLUSIONS: This study demonstrated that it is feasible to insert dental implants and perform an abutment surgery in patients with cancer on HDAR, without the development of MRONJ.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04741906.

Original languageEnglish
JournalOral and Maxillofacial Surgery
Pages (from-to)epub
ISSN1865-1550
DOIs
Publication statusE-pub ahead of print - 27 Jan 2022

Bibliographical note

© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

    Research areas

  • Antiresorptive agents, Cancer, Dental implant, Prosthodontics

ID: 74406410